Publications

Genevant’s leadership in nucleic acid delivery is reflected in a number of peer-reviewed publications authored by our scientists, alone or in collaboration with other researchers.

Lam, et al. (2023)

Optimizing Lipid Nanoparticles for Delivery in Primates

Advanced Materials

DOI/10.1002/adma.202211420

Lam, et al. (2023)

Unsaturated, Trialkyl Ionizable Lipids are Versatile Lipid-Nanoparticle Components for Therapeutic and Vaccine Applications

Advanced Materials

DOI/epdf/10.1002/adma.202209624

Ye, et al. (2023)

Combination treatment of mannose and GalNAc conjugated small interfering RNA protects against lethal Marburg virus infection

Molecular Therapy

DOI.org/10.1016/j.ymthe.2022.09.009

Gatechompol (2022)

Safety and immunogenicity of a prefusion non-stabilized spike protein mRNA COVID-19 vaccine: a phase I trial

Nature Microbiology

DOI: 10.1038/s41564-022-01271-0

Prompetchara, et al. (2022)

Immunogenicity and protective efficacy of SARS-CoV-2 mRNA vaccine encoding secreted non-stabilized spike in female mice

Nature Communications

DOI: 10.1038/s41467-023-37795-0

Muramatsu, et al. (2022)

Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine

Molecular Therapy

DOI: 10.1016/j.ymthe.2022.09.009

Parhiz, et al. (2022)

Added to pre-existing inflammation, mRNA-lipid nanoparticles induce inflammation exacerbation (IE)

Journal of controlled Release

DOI: 10.1016/j.jconrel.2021.12.027

Holland, et al. (2021)

Ligand conjugate SAR and enhanced delivery in NHP

Molecular Therapy

DOI: https://doi.org/10.1016/j.ymthe.2021.06.002